Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Herman

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Journal of the California Dental Association|January 23, 2016
Professionalism at the CrossroadsGary Herman
Journal of the American Dental Association (1939)|June 29, 2016
The ethical issues of saying good-bye to a patientGary Herman
The AAPS Journal|August 8, 2008
Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetesRajesh Krishna, Gary Herman, John A Wagner
Journal of the California Dental Association|February 26, 2008
Journal's impartiality questionedJason W Pair, Gary Herman, George Maranon, et al.
The Journal of Pain|November 29, 2008
Effect of morphine and pregabalin compared with diphenhydramine hydrochloride and placebo on hyperalgesia and allodynia induced by intradermal capsaicin in healthy male subjectsHao Wang, James Bolognese, Nicole Calder, et al.
The Journal of Antimicrobial Chemotherapy|May 20, 2004
Safety and tolerability of ertapenemHedy Teppler, Richard M Gesser, Ian R Friedland, et al.
Journal of Clinical Pharmacology|January 25, 2007
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjectsRajesh Krishna, Arthur Bergman, Patrick Larson, et al.
Journal of Clinical Pharmacology|June 20, 2020
Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 StudyFrédéric Vanhoutte, Su Liang, Marcella Ruddy, et al.
Biopharmaceutics & Drug Disposition|June 19, 2007
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteersArthur Bergman, David Ebel, Fang Liu, et al.
Psychopharmacology|June 7, 2011
Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humansWilliam Cho, Paul Maruff, John Connell, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Journal of the California Dental Association|January 23, 2016
Professionalism at the CrossroadsGary Herman
Journal of the American Dental Association (1939)|June 29, 2016
The ethical issues of saying good-bye to a patientGary Herman
The AAPS Journal|August 8, 2008
Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetesRajesh Krishna, Gary Herman, John A Wagner
Journal of the California Dental Association|February 26, 2008
Journal's impartiality questionedJason W Pair, Gary Herman, George Maranon, et al.
The Journal of Pain|November 29, 2008
Effect of morphine and pregabalin compared with diphenhydramine hydrochloride and placebo on hyperalgesia and allodynia induced by intradermal capsaicin in healthy male subjectsHao Wang, James Bolognese, Nicole Calder, et al.
The Journal of Antimicrobial Chemotherapy|May 20, 2004
Safety and tolerability of ertapenemHedy Teppler, Richard M Gesser, Ian R Friedland, et al.
Journal of Clinical Pharmacology|January 25, 2007
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjectsRajesh Krishna, Arthur Bergman, Patrick Larson, et al.
Journal of Clinical Pharmacology|June 20, 2020
Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 StudyFrédéric Vanhoutte, Su Liang, Marcella Ruddy, et al.
Biopharmaceutics & Drug Disposition|June 19, 2007
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteersArthur Bergman, David Ebel, Fang Liu, et al.
Psychopharmacology|June 7, 2011
Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humansWilliam Cho, Paul Maruff, John Connell, et al.
Pageof 3